Pilot Study for New Chronic Pain Treatment Protocol with Nexstim NBT® System Starts in Helsinki University Hospital
Company Announcement, Inside Information, Helsinki, 25 September 2020 at 9.50 am (EEST)
Pilot Study for New Chronic Pain Treatment Protocol with Nexstim NBT® System Starts in Helsinki University Hospital
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that a pilot study on the use of accelerated iTBS protocol in treatment of therapy resistant, chronic neuropathic pain with Nexstim NBT® System is starting at Helsinki University Hospital.
Accelerated iTBS means transcranial magnetic stimulation (TMS) therapy where stimulation is given several times a day during individual days. In conventional TMS therapy for pain, stimulation is given once a day during several weeks.
In the Helsinki University Hospital pilot study, the effectiveness of the accelerated iTBS protocol will be tested in 5-10 patients. They are suffering from therapy resistant, chronic neuropathic pain and have not benefited from prior 10 Hz rTMS treatment targeted to the motor cortex.
Their treatment will begin in the last quarter of this year and all the treatments are estimated to be completed in first half of 2021. The results of the study will be announced as soon as possible after their completion.
Mikko Karvinen, CEO of Nexstim, commented: “Starting a pilot study using accelerated iTBS protocol treatment in therapy resistant chronic pain is one of our strategic goals for 2020. Helsinki University Hospital has successfully used Nexstim NBT® system with SmartFocus® TMS in pain therapy for a long time already – we are very delighted that they have now decided to conduct this pilot study.”
Further information is available on the website www.nexstim.comor by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
Erik Penser Bank AB (Certified Adviser)
+46 8 463 83 00
certifiedadviser@penser.se
About Nexstim Plc
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information please visit www.nexstim.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
FRO – Filing of Annual Report26.4.2024 22:36:43 CEST | Press release
Frontline plc (the “Company”) announces the filing of its annual report for the year ended December 31, 2023. The annual report can be downloaded from the Company’s website www.frontlineplc.cy or from the link below. Additionally, shareholders can request a hard copy of our complete audited financial statements free of charge by writing to us at: John Kennedy 8 Iris Building, 7th floor, Flat/Office 740B, 3106, Limassol, Cyprus. or sending an e-mail to ir@frontmgt.no April 26, 2024 Frontline plc Limassol, Cyprus. Questions should be directed to: Lars H. Barstad: Chief Executive Officer, Frontline Management AS +47 23 11 40 00 Inger M. Klemp: Chief Financial Officer, Frontline Management AS +47 23 11 40 00 This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. Attachments 5493004BCIKYU1YL3H63-2023-12-31-enAnnual Report 2023
Kallelse till årsstämma 2024 i Fingerprint Cards AB (publ)26.4.2024 22:16:32 CEST | Pressemelding
Aktieägarna i Fingerprint Cards AB (publ), org. nr. 556154-2381 (”Bolaget” eller ”Fingerprint”), kallas härmed till årsstämma klockan 15.00 tisdagen den 28 maj 2024 på GT30 (mötesrum ”Bond”), Grev Turegatan 30 i Stockholm. Styrelsen har, i enlighet med Bolagets bolagsordning, beslutat att aktieägarna före årsstämman ska ha möjlighet att utöva sin rösträtt genom poströstning. Aktieägare kan därmed välja att utöva sin rösträtt vid stämman personligen, genom ombud eller genom poströstning. A. Rätt att delta på stämman Aktieägare som önskar delta vid årsstämman ska: vara införd i den av Euroclear Sweden AB förda aktieboken måndagen den 20 maj 2024, och anmäla sin avsikt att delta vid stämman till Bolaget i enlighet med anvisningarna under avsnitt ”B. Anmälan för deltagande personligen eller genom ombud” senast onsdagen den 22 maj 2024, eller avge en poströst i enlighet med anvisningarna under rubriken ”C.Anvisningar för poströstning” senast onsdagen den 22 maj 2024. För att ha rätt att del
Notice to attend the 2024 Annual General Meeting of Fingerprint Cards AB (publ)26.4.2024 22:16:32 CEST | Press release
The shareholders of Fingerprint Cards AB (publ), Corp. Reg. No. 556154-2381 (hereinafter referred to as the “Company” or “Fingerprint”)), are hereby invited to attend the Annual General Meeting (“AGM” or the “Meeting”) to be held at 3:00 p.m. on Tuesday, May 28, 2024, at GT30 (meeting room “Bond”), Grev Turegatan 30 in Stockholm. The Board of Directors has decided, pursuant to the Company’s articles of association, that shareholders shall also have the right to exercise their voting rights by postal voting. Shareholders may therefore choose to exercise their voting rights at the Meeting by attending in person, through a proxy or by postal voting. A. Right to participate in the Meeting In order to participate in the Meeting, a shareholder shall: be registered in the register of shareholders maintained by Euroclear Sweden AB as of Monday, May 20, 2024, and give notice of attendance at the Meeting to the Company in accordance with the instructions set out in the section “B. Notice of atte
Fingerprints announces partially guaranteed rights issue of up to approximately SEK 310 million, agreement on early redemption of its convertible bonds, bridge loan of SEK 60 million and preliminary financial information for Q1 202426.4.2024 22:00:00 CEST | Press release
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE. The Board of Directors of Fingerprint Cards AB ("Fingerprints" or the "Company") has resolved on a partially guaranteed issue of new shares of series B (“B-shares”) of up to approximately SEK 310 million with preferential rights for its existing shareholders, subject to subsequent approval from the annual general meeting in the Company to be held on 28 May 2024 (the “Rights Issue”). The Rights Issue is subject to subscription undertakings and guarantee commitments in a total amount of up to SEK 275 million. The Board of Directors of Fingerprints has also entered into an agreement with an entity managed by
Fingerprints offentliggör delvis garanterad företrädesemission om upp till cirka 310 MSEK, avtal om förtida inlösen av dess konvertibler, brygglån om 60 MSEK samt preliminär finansiell information för Q1 202426.4.2024 22:00:00 CEST | Pressemelding
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, I ELLER TILL USA, AUSTRALIEN, BELARUS, HONGKONG, JAPAN, KANADA, NYA ZEELAND, RYSSLAND, SINGAPORE, SYDAFRIKA ELLER NÅGON ANNAN JURISDIKTION DÄR DISTRIBUTION AV DETTA PRESSMEDDELANDE SKULLE VARA OTILLÅTEN, KRÄVA REGISTRERING ELLER ANNAN ÅTGÄRD ENLIGT TILLÄMPLIG LAG. VÄNLIGEN SE VIKTIG INFORMATION I SLUTET AV PRESSMEDDELANDET. Styrelsen i Fingerprint Cards AB ("Fingerprints" eller "Bolaget") har beslutat om en delvis garanterad nyemission av aktier av serie B ("B-aktier") om upp till cirka 310 MSEK med företrädesrätt för dess befintliga aktieägare, under förutsättning av efterföljande godkännande från årsstämman i Bolaget den 28 maj 2024 ("Företrädesemissionen"). Företrädesemissionen omfattas av tecknings- och garantiåtaganden till ett sammanlagt belopp om upp till 275 MSEK. Styrelsen i Fingerprints har även ingått avtal med en entitet som förvaltas av Heights Capital Management, Inc. ("HCM"